Our latest data demonstrates a limit of detection more than an order of magnitude better than the current industry benchmark, while maintaining 100% molecular specificity at that level of sensitivity

This research demonstrates the potential of liquid biopsy to enable more precise, non-invasive treatment selection, helping match patients to the most effective therapies while reducing reliance on invasive tissue biopsies.

This poster highlights Wobble Genomics’ long-read RNA sequencing platform for precise profiling of HER2 expression in breast cancer. By capturing full-length RNA transcripts, the approach enables isoform-level resolution, revealing detailed expression patterns that correlate strongly with standard IHC classifications in tumour tissue. Importantly, the study also demonstrates the potential to assess HER2 status non-invasively from blood samples, addressing a key unmet clinical need. The results show improved diagnostic accuracy and deeper insight into transcript diversity, supporting more informed patient stratification and treatment selection for HER2-targeted therapies.

This poster presents the development and analytical validation of a novel long-read RNA sequencing platform designed to detect low-abundance cancer transcripts directly from whole blood. By overcoming key limitations of traditional short-read approaches, the technology enables sensitive, full-length profiling of both short and long RNA species, even within complex biological backgrounds. The study demonstrates strong performance in detection sensitivity, precision, and transcript coverage, while also highlighting the platform’s ability to uncover clinically relevant isoforms in important cancer genes such as HER2 and TROP2. Collectively, these advances position the platform as a powerful tool for liquid biopsy applications, supporting improved cancer diagnostics, treatment monitoring, and precision medicine development.

Wobble Genomics presents a highly sensitive long-read transcriptomics platform for non-invasive profiling of breast cancer from blood. Leveraging its proprietary Level-Up technology, the platform enables comprehensive detection of cancer-specific RNA isoforms, including clinically relevant HER2 variants, with strong concordance to tumour status. The study demonstrates the potential of liquid biopsy to refine patient stratification, expand eligibility for targeted therapies, and monitor treatment response over time—offering a powerful new approach to precision oncology.

This poster presents a novel liquid biopsy platform that leverages advanced long-read RNA sequencing to uncover cancer-specific transcript isoforms in breast cancer patients. By combining comprehensive transcriptome profiling with proprietary analytical approaches, the technology enables highly accurate detection of tumor-derived signals from blood samples, revealing thousands of previously uncharacterized RNA variants. The platform not only improves diagnostic precision but also identifies new therapeutic targets, supporting applications across early detection, treatment monitoring, and drug development.

This poster showcases Wobble Genomics’ novel liquid biopsy platform, which combines long-read RNA sequencing with proprietary Level-Up normalization to uncover previously undetectable RNA signals in blood. Using whole transcriptome profiling from breast cancer patients and controls, the study demonstrates how full-length RNA can significantly improve early cancer detection. By revealing hundreds of thousands of novel transcripts and enhancing predictive accuracy, this approach opens new avenues for sensitive diagnostics and deeper insights into cancer biology.

Wobble Genomics presents a novel approach to RNA sequencing with its Level-Up full-length cDNA normalization technology, designed to reveal the full complexity of the transcriptome. By reducing the dominance of highly abundant transcripts and enhancing the detection of low-abundance isoforms, Level-Up significantly improves gene discovery and transcript coverage without requiring prior target selection. Compatible with long-read sequencing platforms, this method increases sensitivity, lowers sequencing costs, and enables a more complete and unbiased view of RNA biology—unlocking deeper insights for research and clinical applications.